26. January 2023

TRR259 publication part of the podcast from "Circulation" Circulation podcast

The American Heart Association's journal Circulation provides podcasts of recently published research articles in the field of cardiovascular medicine. The podcasts are intended for a general audience and provide a brief overview of the study's main findings and their potential implications for clinical practice. They also include interviews with the study's authors and other experts to provide additional context and perspective on the research. In the following podcast, a study of our TRR259 members was discussed.

Link to the podcast: https://www.ahajournals.org/circ/podcasts

Information about the podcast

Circulation January 24, 2023 Issue
Released: Jan 23, 2023
 Please join author Subodh Verma and Guest Editor Christopher Granger as they discuss the article "Empagliflozin and Left Ventricular Remodeling in People Without Diabetes: Primary Results of the EMPA-HEART 2 CardioLink-7 Randomized Clinical Trial."

Publication

Hosen MR, Goody PR, Zietzer A, Xiang X, Niepmann ST, Sedaghat A, Tiyerili V, Chennupati R, Moore JB 4th, Boon RA, Uchida S, Sinning JM, Zimmer S, Latz E, Werner N, Nickenig G, Jansen F. Circulating MicroRNA-122-5p Is Associated With a Lack of Improvement in Left Ventricular Function After Transcatheter Aortic Valve Replacement and Regulates Viability of Cardiomyocytes Through Extracellular Vesicles. Circulation. 2022 Jul 8:101161CIRCULATIONAHA122060258. doi: 10.1161/CIRCULATIONAHA.122.060258

Summary of the Publication 

This study investigated the association between the level of a specific microRNA (miRNA-122-5p) in the bloodstream and the improvement in left ventricular function after transcatheter aortic valve replacement (TAVR) surgery. The study found that patients with higher levels of miRNA-122-5p in their blood did not show as much improvement in left ventricular function after TAVR surgery compared to patients with lower levels of the miRNA. Additionally, the study discovered that miRNA-122-5p regulates the viability of cardiomyocytes (heart muscle cells) through extracellular vesicles. The study's authors suggest that measuring the level of miRNA-122-5p in the blood could be used as a biomarker to predict which patients are less likely to benefit from TAVR surgery, and that targeting miRNA-122-5p may be a potential therapeutic approach to improve outcomes after TAVR.